<DOC>
	<DOC>NCT02307578</DOC>
	<brief_summary>The main objective of the Extended Access Program (EAP) is to ensure that subjects participating in Study E2007-G000-332 continue to have access to perampanel until the time perampanel becomes commercially available in the country in which they reside.</brief_summary>
	<brief_title>Extended Access Program for Subjects Completing Perampanel StudyE2007-G000-332</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<criteria>Inclusion criteria: 1. Subjects participating in Study E2007G000332 (NCT01393743), with at least 52 weeks of total exposure to perampanel, and who in the opinion of the treating physician continue to benefit from treatment with perampanel. Exclusion criteria: 1. Female subjects who are nursing, pregnant, or planning to become pregnant.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Perampanel</keyword>
	<keyword>Fycompa</keyword>
	<keyword>Primary Generalized Tonic-Clonic Seizures</keyword>
	<keyword>E2007-G000-332</keyword>
	<keyword>E2007</keyword>
</DOC>